American Pain Society Urges FDA to Modify Restricted Distribution Program

In a letter to the Food and Drug Administration, the American Pain Society (APS) petitioned the agency, on behalf of the terminally ill and their families, to modify a restricted distribution program for the newly approved pain medication Onsolis, a short-acting product that delivers fentanyl through the mouth's mucous membranes.

"We recognize that some opioid products because of their potency and potential for abuse and unintentional death may require additional limitations to assure safe use, but restrictions for Onsolis and perhaps other medications could affect access to the best quality pain relief for patients suffering from cancer-related pain at the end of life and inhibit physicians from delivering the best therapeutic care," APS wrote.

On July 16, FDA approved Onsolis but required that it be made available only through a restricted distribution program from specialty pharmacies. APS said the restriction poses serious concerns for terminal patients in hospitals. "Trans-mucosal fentanyl is used in acute situations and often at the end of life," APS noted, "and not allowing hospital and institutional pharmacies to stock these medications for immediate use denies access to a medication that might be the best option to ease acute or chronic pain in the final days of life."

APS also said patient education requirements for Onsolis are overly burdensome because many terminal cancer patients are cognitively impaired, may not have family or caregivers, and are living in institutional settings. "In these cases, a counseling requirement is impractical and will have unintended consequences on clinical decision making, access to care, and the quality of pain relief," APS wrote.

APS urged FDA to solicit advice from pain and palliative care organizations to help mitigate the unintended consequences of the drug access restrictions, known as REMS. APS believes it is vital that any attempts to reduce the number of opioid-associated deaths per year not unnecessarily increase suffering for the millions of patients worldwide who require opioid treatment for their severe acute, chronic, and/or cancer-related pain.

In February, FDA announced it will require manufacturers of 24 short and long acting opioid medications to establish comprehensive risk management plans to reduce overdoses. The agency plans to issue guidelines to the companies for developing REMS polices that will comply with FDA's standards. The approval of Onsolis with restrictions is the first implementation of a REMS action for an opioid medication.

In a previously published letter to FDA dated June 29, APS urged FDA to consider five key standards when formulating its REMS guidelines:

  1. REMS should cover the entire class of opioid medications. An attempt to regulate certain drugs will drive prescribers, users, and especially misusers to other less stringently regulated opioids.
  2. Mandated and potentially stigmatizing patient registries for opioids should be avoided because there is no evidence showing they diminish abuse and misuse. Instead, enhancements to existing state prescription monitoring programs would be a better option.
  3. REMS should be measurable and reversible to be effective in curbing abuse and misuse of opioids while assuring medication access for legitimate pain patients.
  4. An educational curriculum for prescribers and dispensers of opioids should be offered through a variety of channels. Consider requiring demonstration of competence in basic opioid pharmacology for issuance of a DEA prescribing license.
  5. Educate the public on the dangers of sharing opioid prescription drugs and other drug abuse behaviors to help reduce drug diversion.
  6. APS also suggested that consumer education should be combined with allowable, voluntary give-back programs that enable patients to return unused prescriptions and prevent unintended diversion from their medicine cabinets.

Download Center

HTML - No Current Item Deck
  • Free Safety Management Software Demo

    IndustrySafe Safety Management Software helps organizations to improve safety by providing a comprehensive toolset of software modules to help businesses identify trouble spots; reduce claims, lost days, OSHA fines; and more.

  • The Top 5 Safety and Technology Trends to Watch

    Get the latest on trends you can expect to hear more about in 2019, including continued growth of mobile safety applications, wearable technology, and smart PPE; autonomous vehicles; pending OSHA recordkeeping rulemaking; and increased adoption of international safety standard, ISO 45001.

  • Analyze Incident Data

    Collect relevant incident data, analyze trends, and generate accurate regulatory reports, including OSHA 300, 300A, and 301 logs, through IndustrySafe’s extensive incident reporting and investigation module.

  • Safety Training 101

    When it comes to safety training, no matter the industry, there are always questions regarding requirements and certifications. We’ve put together a guide on key safety training topics, requirements for certifications, and answers to common training questions.

  • Conduct EHS Inspections and Audits

    Record and manage your organization’s inspection data with IndustrySafe’s Inspections module. IndustrySafe’s pre-built forms and checklists may be used as is, or can be customized to better suit the needs of your organization.

  • Industry Safe
comments powered by Disqus

OH&S Digital Edition

  • OHS Magazine Digital Edition - January 2019

    January / February 2019


      Production vs. Safety 
      Meeting the Requirements for Emergency Equipment
      The State of Contractor Safety
      The Three Keys to Effective Chemical Management
    View This Issue